🇺🇸 FDA
Patent

US 8183009

Assaying cellular markers for the evaluation of tumors

granted A61PA61P17/02A61P31/00

Quick answer

US patent 8183009 (Assaying cellular markers for the evaluation of tumors) held by Precision Therapeutics, Inc. expires Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Precision Therapeutics, Inc.
Grant date
Tue May 22 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 17 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
7
CPC classes
A61P, A61P17/02, A61P31/00, A61P35/00, A61P37/02